Omeros Corporation (FRA:3O8)
Germany · Delayed Price · Currency is EUR | Market Cap | 590.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.26M |
| Shares Out | n/a |
| EPS (ttm) | -1.71 |
| PE Ratio | n/a |
| Forward PE | 20.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 548 |
| Open | 8.28 |
| Previous Close | 8.32 |
| Day's Range | 8.28 - 8.28 |
| 52-Week Range | 2.49 - 12.39 |
| Beta | n/a |
| RSI | 65.39 |
| Earnings Date | Mar 31, 2026 |
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind... [Read more]
News
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid
Omeros stock rises after a $340 million deal with Novo Nordisk. Learn about its improved risk profile and covered call trade potential.
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript
Omeros Corporation (OMER) Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsGregory Demopulos - Co-Founder, Chairman, CEO &...
Omeros (OMER) Q3 2025 Earnings Call Transcript
Omeros (OMER) Q3 2025 Earnings Call Transcript
Omeros (OMER) Receives Analyst 'Buy' Rating with Stable Price Target | OMER Stock News
Omeros (OMER) Receives Analyst 'Buy' Rating with Stable Price Target | OMER Stock News
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 500 points on Friday. Shares of Legence Corp (NASDAQ: LGN) rose sharply during Friday's session after delivering mixed third-quarter...
Omeros Awaits FDA Decision On Lead Drug Candidate Narsoplimab Next Month
(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the th...
Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges
Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges
Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close
(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates.
Q3 2025 Omeros Corp Earnings Call Transcript
Q3 2025 Omeros Corp Earnings Call Transcript
Omeros (OMER) Set for Transformative Growth with Key Developments
Omeros (OMER) Set for Transformative Growth with Key Developments
Omeros Corporation Reports Third Quarter 2025 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which includ...
Omeros Q3 2025 Earnings Preview
Examining the Future: Omeros's Earnings Outlook
Omeros (NASDAQ: OMER) is preparing to release its quarterly earnings on Thursday, 2025-11-13. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Om...
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025,...
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglo...
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bank...
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on We...
Can OMER stock retain Novo Nordisk driven gains over the long-term?
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER's...
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disord...
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement fo...
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and...
Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Catherine A. Melfi - Chief Regulatory Officer & VP of Regulatory Affairs and Quality ...